Investments in the US Market
Novartis, the Swiss pharmaceutical company, plans to invest 23 billion USD in the expansion of its production and research capacities in the United States over the next five years. These investments aim to strengthen local production and reduce reliance on imports. The focus is on the construction of seven new production facilities as well as the expansion of ten sites in the USA. As a result, Novartis will be able to manufacture 100 percent of its key medicines sold in the US market entirely in the USA.
Job Creation
The planned investments are expected to create 1,000 new internal jobs at Novartis and stimulate about 4,000 additional jobs in the USA. This represents a significant contribution to the economic development in the regions where these new facilities will be established.
Research and Innovation Center
Another highlight of the investments is the construction of a new research and innovation center for biomedicine in San Diego, California. Scheduled to open between 2028 and 2029, it will complement the existing research centers in Cambridge, Massachusetts, and Basel, further enhancing Novartis’s technological innovation capabilities.
Approval Success for Pluvicto
In addition to the investments, Novartis has celebrated a significant approval success for the cancer drug Pluvicto. Pluvicto is a radiopharmaceutical drug for the treatment of certain forms of prostate cancer and represents an important milestone in the company’s innovative cancer therapy research.
Significance for Investors
These developments are particularly important for investors interested in corporate news from publicly traded companies. The strategic investments and the approval success for Pluvicto underscore Novartis’s forward-looking orientation and strengthen investor confidence by promoting the company’s long-term competitiveness.